CompletedPhase 1

A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus

Australia, Mexico129 participantsStarted 2021-04-29

Plain-language summary

This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult participants and obese participants with T2DM.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Males or females * 18-65 years old, inclusive * BMI 27.0-40.0, inclusive * Stable body weight for 2 months Exclusion Criteria: * Significant medical history * Uncontrolled hypertension * History of malignancy

What they're measuring

Incidence of Treatment-Emergent Adverse Events as assessed by self-report

Timeframe: Baseline up to 24 weeks

Trial details

NCT IDNCT04838405

SponsorCarmot Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-06-18

View on ClinicalTrials.gov More Diabetes trials